Pathogenesis of myeloma
- PMID: 21261519
- DOI: 10.1146/annurev-pathol-011110-130249
Pathogenesis of myeloma
Abstract
Multiple myeloma (MM) is a neoplasm of post-germinal center, terminally differentiated B cells. It is characterized by a multifocal proliferation of clonal, long-lived plasma cells within the bone marrow (BM) and associated skeletal destruction, serum monoclonal gammopathy, immune suppression, and end-organ sequelae. MM is preceded by an age-progressive premalignant condition termed monoclonal gammopathy of undetermined significance. Unlike the genomes of most hematological malignancies, and similar to those of solid-tissue neoplasms, MM genomes are typified by numerous structural and numerical chromosomal aberrations as well as mutations in a number of oncogenes and tumor-suppressor genes, some of which have been linked to disease pathogenesis and clinical behavior. Recent studies have also defined the importance of interactions between the MM cells and their BM microenvironment, dysregulation in signaling pathways and in a specialized subpopulation of cells within the tumor (termed myeloma cancer stem cells) for tumor cell growth and survival, and the development of resistance to therapy.
Similar articles
-
The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.Clin Cancer Res. 2011 Apr 1;17(7):1692-700. doi: 10.1158/1078-0432.CCR-10-1066. Epub 2011 Feb 16. Clin Cancer Res. 2011. PMID: 21325290
-
Molecular pathogenesis of multiple myeloma and its premalignant precursor.J Clin Invest. 2012 Oct;122(10):3456-63. doi: 10.1172/JCI61188. Epub 2012 Oct 1. J Clin Invest. 2012. PMID: 23023717 Free PMC article. Review.
-
From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.Cancer Res. 2018 May 15;78(10):2449-2456. doi: 10.1158/0008-5472.CAN-17-3115. Epub 2018 Apr 27. Cancer Res. 2018. PMID: 29703720 Review.
-
Aetiology: The path to disease.Nature. 2011 Dec 14;480(7377):S54-5. doi: 10.1038/480S54a. Nature. 2011. PMID: 22169806 No abstract available.
-
Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.Recent Results Cancer Res. 2011;183:39-86. doi: 10.1007/978-3-540-85772-3_3. Recent Results Cancer Res. 2011. PMID: 21509680 Review.
Cited by
-
Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells.PLoS One. 2013;8(3):e59756. doi: 10.1371/journal.pone.0059756. Epub 2013 Mar 21. PLoS One. 2013. PMID: 23555770 Free PMC article.
-
Mithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factors.PLoS One. 2013 May 7;8(5):e62818. doi: 10.1371/journal.pone.0062818. Print 2013. PLoS One. 2013. PMID: 23667526 Free PMC article.
-
Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.Clin Cancer Res. 2012 Nov 15;18(22):6260-70. doi: 10.1158/1078-0432.CCR-12-1708. Epub 2012 Oct 3. Clin Cancer Res. 2012. PMID: 23035210 Free PMC article.
-
The interplay between microRNAs and Nrf2 signaling in human cancers.Cancer Cell Int. 2024 Jul 5;24(1):234. doi: 10.1186/s12935-024-03430-1. Cancer Cell Int. 2024. PMID: 38970040 Free PMC article. Review.
-
MALDI-TOF analysis of blood serum proteome can predict the presence of monoclonal gammopathy of undetermined significance.PLoS One. 2018 Aug 2;13(8):e0201793. doi: 10.1371/journal.pone.0201793. eCollection 2018. PLoS One. 2018. PMID: 30071092 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
